| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | ubiquitin-protein transferase activity | HECTD4 BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 6.53e-06 | 473 | 104 | 12 | GO:0004842 |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor | 7.54e-06 | 8 | 104 | 3 | GO:0033695 | |
| GeneOntologyMolecularFunction | caffeine oxidase activity | 7.54e-06 | 8 | 104 | 3 | GO:0034875 | |
| GeneOntologyMolecularFunction | ubiquitin-like protein transferase activity | HECTD4 BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 1.44e-05 | 512 | 104 | 12 | GO:0019787 |
| GeneOntologyMolecularFunction | aminoacyltransferase activity | HECTD4 BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 2.11e-05 | 532 | 104 | 12 | GO:0016755 |
| GeneOntologyMolecularFunction | estrogen 16-alpha-hydroxylase activity | 2.20e-05 | 11 | 104 | 3 | GO:0101020 | |
| GeneOntologyMolecularFunction | (R)-limonene 6-monooxygenase activity | 2.69e-05 | 2 | 104 | 2 | GO:0052741 | |
| GeneOntologyMolecularFunction | (S)-limonene 6-monooxygenase activity | 2.69e-05 | 2 | 104 | 2 | GO:0018675 | |
| GeneOntologyMolecularFunction | (S)-limonene 7-monooxygenase activity | 2.69e-05 | 2 | 104 | 2 | GO:0018676 | |
| GeneOntologyMolecularFunction | limonene monooxygenase activity | 2.69e-05 | 2 | 104 | 2 | GO:0019113 | |
| GeneOntologyMolecularFunction | P-type manganese transporter activity | 2.69e-05 | 2 | 104 | 2 | GO:0140613 | |
| GeneOntologyMolecularFunction | retinoic acid 4-hydroxylase activity | 4.79e-05 | 14 | 104 | 3 | GO:0008401 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups | 5.97e-05 | 15 | 104 | 3 | GO:0016725 | |
| GeneOntologyMolecularFunction | folic acid receptor activity | 8.03e-05 | 3 | 104 | 2 | GO:0061714 | |
| GeneOntologyMolecularFunction | transition metal ion binding | ZNF93 CYP2C19 CYP2C8 CYP2C9 NT5E ZNF195 MDM4 TRIM22 TRIM5 ATP2C1 TRAFD1 BRCA1 SLFN13 MIB1 MTARC2 SLFN11 PLSCR2 | 1.33e-04 | 1189 | 104 | 17 | GO:0046914 |
| GeneOntologyMolecularFunction | ubiquitin protein ligase activity | 1.42e-04 | 372 | 104 | 9 | GO:0061630 | |
| GeneOntologyMolecularFunction | arachidonate 11,12-epoxygenase activity | 1.60e-04 | 4 | 104 | 2 | GO:0008405 | |
| GeneOntologyMolecularFunction | linoleic acid epoxygenase activity | 1.60e-04 | 4 | 104 | 2 | GO:0071614 | |
| GeneOntologyMolecularFunction | ubiquitin-like protein ligase activity | 2.35e-04 | 398 | 104 | 9 | GO:0061659 | |
| GeneOntologyMolecularFunction | arachidonate epoxygenase activity | 2.57e-04 | 24 | 104 | 3 | GO:0008392 | |
| GeneOntologyMolecularFunction | fatty acid omega-1 hydroxylase activity | 2.66e-04 | 5 | 104 | 2 | GO:0120502 | |
| GeneOntologyMolecularFunction | long-chain fatty acid omega-1 hydroxylase activity | 2.66e-04 | 5 | 104 | 2 | GO:0120319 | |
| GeneOntologyMolecularFunction | arachidonate 14,15-epoxygenase activity | 2.66e-04 | 5 | 104 | 2 | GO:0008404 | |
| GeneOntologyMolecularFunction | arachidonate monooxygenase activity | 3.67e-04 | 27 | 104 | 3 | GO:0008391 | |
| GeneOntologyMolecularFunction | acyltransferase activity | HECTD4 BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 7.04e-04 | 775 | 104 | 12 | GO:0016746 |
| GeneOntologyMolecularFunction | steroid hydroxylase activity | 7.30e-04 | 34 | 104 | 3 | GO:0008395 | |
| GeneOntologyMolecularFunction | aromatase activity | 7.96e-04 | 35 | 104 | 3 | GO:0070330 | |
| GeneOntologyMolecularFunction | tRNA binding | 1.11e-03 | 87 | 104 | 4 | GO:0000049 | |
| GeneOntologyMolecularFunction | manganese ion transmembrane transporter activity | 1.18e-03 | 10 | 104 | 2 | GO:0005384 | |
| GeneOntologyMolecularFunction | P-type calcium transporter activity | 1.43e-03 | 11 | 104 | 2 | GO:0005388 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 2.12e-03 | 49 | 104 | 3 | GO:0016712 | |
| GeneOntologyMolecularFunction | enzyme activator activity | 2.23e-03 | 656 | 104 | 10 | GO:0008047 | |
| GeneOntologyMolecularFunction | zinc ion binding | ZNF93 NT5E ZNF195 MDM4 TRIM22 TRIM5 TRAFD1 BRCA1 SLFN13 MIB1 SLFN11 PLSCR2 | 2.30e-03 | 891 | 104 | 12 | GO:0008270 |
| GeneOntologyMolecularFunction | enzyme regulator activity | PSAP LRRK2 BIRC3 NBN BRCC3 WFDC10B CHM GRM5 TBC1D8 VPS9D1 ARHGAP5 GLMN WFDC3 NOD1 PRKAR1B ARHGAP21 | 2.67e-03 | 1418 | 104 | 16 | GO:0030234 |
| GeneOntologyMolecularFunction | GTPase activator activity | 3.41e-03 | 279 | 104 | 6 | GO:0005096 | |
| GeneOntologyMolecularFunction | CARD domain binding | 3.47e-03 | 17 | 104 | 2 | GO:0050700 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 4.77e-03 | 614 | 104 | 9 | GO:0140657 | |
| GeneOntologyMolecularFunction | folic acid binding | 4.80e-03 | 20 | 104 | 2 | GO:0005542 | |
| GeneOntologyBiologicalProcess | regulation of viral entry into host cell | 8.03e-06 | 55 | 103 | 5 | GO:0046596 | |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation or removal | LRRK2 HECTD4 BIRC3 NBN BRCC3 USP37 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 USP48 RNF133 | 9.93e-06 | 1009 | 103 | 17 | GO:0070647 |
| GeneOntologyBiologicalProcess | positive regulation of canonical NF-kappaB signal transduction | 1.16e-05 | 213 | 103 | 8 | GO:0043123 | |
| GeneOntologyBiologicalProcess | modulation by symbiont of entry into host | 1.45e-05 | 62 | 103 | 5 | GO:0052372 | |
| GeneOntologyBiologicalProcess | post-translational protein modification | LRRK2 HECTD4 BIRC3 NBN BRCC3 USP37 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 USP48 RNF133 | 2.22e-05 | 1074 | 103 | 17 | GO:0043687 |
| GeneOntologyBiologicalProcess | positive regulation of autophagy | 2.60e-05 | 173 | 103 | 7 | GO:0010508 | |
| GeneOntologyBiologicalProcess | regulation of biological process involved in symbiotic interaction | 3.68e-05 | 75 | 103 | 5 | GO:0043903 | |
| GeneOntologyBiologicalProcess | omega-hydroxylase P450 pathway | 4.23e-05 | 14 | 103 | 3 | GO:0097267 | |
| GeneOntologyBiologicalProcess | protein ubiquitination | LRRK2 HECTD4 BIRC3 NBN MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 5.05e-05 | 811 | 103 | 14 | GO:0016567 |
| GeneOntologyBiologicalProcess | tRNA decay | 9.34e-05 | 18 | 103 | 3 | GO:0016078 | |
| GeneOntologyBiologicalProcess | positive regulation of NF-kappaB transcription factor activity | 1.11e-04 | 151 | 103 | 6 | GO:0051092 | |
| GeneOntologyBiologicalProcess | regulation of canonical NF-kappaB signal transduction | 1.25e-04 | 298 | 103 | 8 | GO:0043122 | |
| GeneOntologyBiologicalProcess | regulation of viral life cycle | 1.33e-04 | 156 | 103 | 6 | GO:1903900 | |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation | LRRK2 HECTD4 BIRC3 NBN MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 CCAR1 RNF133 | 1.40e-04 | 893 | 103 | 14 | GO:0032446 |
| GeneOntologyBiologicalProcess | peripheral nervous system myelin formation | 1.47e-04 | 4 | 103 | 2 | GO:0032290 | |
| GeneOntologyBiologicalProcess | epoxygenase P450 pathway | 1.74e-04 | 22 | 103 | 3 | GO:0019373 | |
| GeneOntologyBiologicalProcess | defense response to symbiont | BIRC3 DAPK1 BRCC3 CD46 WFDC10B TRIM22 DICER1 TRIM5 RFPL4AL1 WFDC3 RFPL4A NOD1 TRAFD1 SLFN13 MICB SLFN11 SLAMF7 | 2.04e-04 | 1286 | 103 | 17 | GO:0140546 |
| GeneOntologyBiologicalProcess | symbiont entry into host cell | 2.05e-04 | 169 | 103 | 6 | GO:0046718 | |
| GeneOntologyBiologicalProcess | positive regulation of Golgi to plasma membrane protein transport | 2.45e-04 | 5 | 103 | 2 | GO:0042998 | |
| GeneOntologyBiologicalProcess | canonical NF-kappaB signal transduction | 2.51e-04 | 330 | 103 | 8 | GO:0007249 | |
| GeneOntologyBiologicalProcess | symbiont entry into host | 2.56e-04 | 176 | 103 | 6 | GO:0044409 | |
| GeneOntologyBiologicalProcess | sperm-egg recognition | 3.14e-04 | 65 | 103 | 4 | GO:0035036 | |
| GeneOntologyBiologicalProcess | positive regulation of DNA-binding transcription factor activity | 3.38e-04 | 261 | 103 | 7 | GO:0051091 | |
| GeneOntologyBiologicalProcess | regulation of viral process | 3.44e-04 | 186 | 103 | 6 | GO:0050792 | |
| GeneOntologyBiologicalProcess | plasma membrane organization | 3.64e-04 | 188 | 103 | 6 | GO:0007009 | |
| GeneOntologyBiologicalProcess | monoterpenoid metabolic process | 3.66e-04 | 6 | 103 | 2 | GO:0016098 | |
| GeneOntologyBiologicalProcess | defense response to other organism | BIRC3 DAPK1 BRCC3 CD46 WFDC10B TRIM22 DICER1 TRIM5 RFPL4AL1 WFDC3 RFPL4A NOD1 TRAFD1 SLFN13 MICB SLFN11 SLAMF7 | 5.78e-04 | 1407 | 103 | 17 | GO:0098542 |
| GeneOntologyBiologicalProcess | fusion of sperm to egg plasma membrane involved in single fertilization | 5.92e-04 | 33 | 103 | 3 | GO:0007342 | |
| GeneOntologyBiologicalProcess | protein polyubiquitination | 6.21e-04 | 289 | 103 | 7 | GO:0000209 | |
| GeneOntologyBiologicalProcess | protein autoubiquitination | 6.30e-04 | 78 | 103 | 4 | GO:0051865 | |
| GeneOntologyBiologicalProcess | single fertilization | 6.37e-04 | 209 | 103 | 6 | GO:0007338 | |
| Domain | ZF_RING_2 | BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 RNF133 | 5.86e-06 | 298 | 103 | 10 | PS50089 |
| Domain | Znf_RING | BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 RNF133 | 1.28e-05 | 326 | 103 | 10 | IPR001841 |
| Domain | P-type_ATPase_IIA_PMR1 | 3.01e-05 | 2 | 103 | 2 | IPR006413 | |
| Domain | ZF_RING_1 | 3.34e-05 | 291 | 103 | 9 | PS00518 | |
| Domain | RING | 4.81e-05 | 305 | 103 | 9 | SM00184 | |
| Domain | DUF2075 | 9.00e-05 | 3 | 103 | 2 | PF09848 | |
| Domain | DUF2075 | 9.00e-05 | 3 | 103 | 2 | IPR018647 | |
| Domain | ROC_dom | 1.79e-04 | 4 | 103 | 2 | IPR020859 | |
| Domain | ROC | 1.79e-04 | 4 | 103 | 2 | PS51424 | |
| Domain | Znf_RING/FYVE/PHD | BIRC3 MDM4 TRIM22 TRIM5 RFPL4AL1 RFPL4A BRCA1 NEURL1 MIB1 RNF133 | 2.24e-04 | 459 | 103 | 10 | IPR013083 |
| Domain | RDM_domain_RFPL | 2.98e-04 | 5 | 103 | 2 | IPR022723 | |
| Domain | RDM | 2.98e-04 | 5 | 103 | 2 | PF11002 | |
| Domain | Folate_rcpt | 2.98e-04 | 5 | 103 | 2 | IPR004269 | |
| Domain | CARD | 4.83e-04 | 28 | 103 | 3 | PF00619 | |
| Domain | ARM-type_fold | 5.78e-04 | 339 | 103 | 8 | IPR016024 | |
| Domain | Butyrophylin | 6.05e-04 | 70 | 103 | 4 | IPR003879 | |
| Domain | HEAT_REPEAT | 6.05e-04 | 70 | 103 | 4 | PS50077 | |
| Domain | AlbA_2 | 6.21e-04 | 7 | 103 | 2 | PF04326 | |
| Domain | Schlafen | 6.21e-04 | 7 | 103 | 2 | IPR029684 | |
| Domain | Schlafen_AAA_dom | 6.21e-04 | 7 | 103 | 2 | IPR007421 | |
| Domain | CARD | 6.54e-04 | 31 | 103 | 3 | IPR001315 | |
| Domain | ARM-like | 7.43e-04 | 270 | 103 | 7 | IPR011989 | |
| Domain | CARD | 7.88e-04 | 33 | 103 | 3 | PS50209 | |
| Domain | Folate_rec | 8.25e-04 | 8 | 103 | 2 | PF03024 | |
| Domain | Folate_rcpt-like | 8.25e-04 | 8 | 103 | 2 | IPR018143 | |
| Domain | - | 8.45e-04 | 449 | 103 | 9 | 3.30.40.10 | |
| Domain | HAD-like_dom | 9.54e-04 | 79 | 103 | 4 | IPR023214 | |
| Domain | ATPase_P-typ_P_site | 1.02e-03 | 36 | 103 | 3 | IPR018303 | |
| Domain | P_typ_ATPase | 1.02e-03 | 36 | 103 | 3 | IPR001757 | |
| Domain | ATPASE_E1_E2 | 1.02e-03 | 36 | 103 | 3 | PS00154 | |
| Domain | ATPase_P-typ_transduc_dom_A | 1.10e-03 | 37 | 103 | 3 | IPR008250 | |
| Domain | E1-E2_ATPase | 1.10e-03 | 37 | 103 | 3 | PF00122 | |
| Domain | NA-bd_OB-fold | 1.15e-03 | 83 | 103 | 4 | IPR012340 | |
| Domain | ConA-like_dom | 1.35e-03 | 219 | 103 | 6 | IPR013320 | |
| Domain | SPRY | 1.37e-03 | 87 | 103 | 4 | SM00449 | |
| Domain | - | 1.75e-03 | 93 | 103 | 4 | 1.10.533.10 | |
| Domain | SPRY | 1.82e-03 | 94 | 103 | 4 | PF00622 | |
| Domain | SPRY_dom | 1.82e-03 | 94 | 103 | 4 | IPR003877 | |
| Domain | B30.2/SPRY | 1.89e-03 | 95 | 103 | 4 | IPR001870 | |
| Domain | B302_SPRY | 1.89e-03 | 95 | 103 | 4 | PS50188 | |
| Domain | Cyt_P450_E_grp-I | 1.95e-03 | 45 | 103 | 3 | IPR002401 | |
| Domain | DEATH-like_dom | 2.20e-03 | 99 | 103 | 4 | IPR011029 | |
| Domain | P-loop_NTPase | LRRK2 MCM3 DAPK1 DICER1 ARHGAP5 NOD1 SLFN13 CARD11 SLFN11 CHST2 DYNC1LI2 DNM2 | 2.44e-03 | 848 | 103 | 12 | IPR027417 |
| Domain | - | LRRK2 MCM3 DICER1 ARHGAP5 NOD1 SLFN13 CARD11 SLFN11 CHST2 DYNC1LI2 DNM2 | 2.71e-03 | 746 | 103 | 11 | 3.40.50.300 |
| Domain | PI3/4_kinase_CS | 3.02e-03 | 15 | 103 | 2 | IPR018936 | |
| Domain | Cyt_P450_CS | 3.12e-03 | 53 | 103 | 3 | IPR017972 | |
| Domain | GRAM | 3.44e-03 | 16 | 103 | 2 | SM00568 | |
| Domain | - | 3.44e-03 | 16 | 103 | 2 | 1.10.1070.11 | |
| Domain | ATPase_P-typ_TM_dom | 3.44e-03 | 16 | 103 | 2 | IPR023298 | |
| Domain | PI3Kc | 3.44e-03 | 16 | 103 | 2 | SM00146 | |
| Domain | - | 3.44e-03 | 16 | 103 | 2 | 1.20.1110.10 | |
| Domain | CYTOCHROME_P450 | 3.84e-03 | 57 | 103 | 3 | PS00086 | |
| Domain | ATPase_P-typ_cation-transptr_C | 3.88e-03 | 17 | 103 | 2 | IPR006068 | |
| Domain | Cation_ATPase_C | 3.88e-03 | 17 | 103 | 2 | PF00689 | |
| Domain | - | 3.88e-03 | 17 | 103 | 2 | 4.10.75.10 | |
| Domain | WAP | 3.88e-03 | 17 | 103 | 2 | PS51390 | |
| Domain | - | 4.03e-03 | 58 | 103 | 3 | 1.10.630.10 | |
| Domain | p450 | 4.03e-03 | 58 | 103 | 3 | PF00067 | |
| Domain | Cation_ATPase_N | 4.35e-03 | 18 | 103 | 2 | PF00690 | |
| Domain | PI3_PI4_kinase | 4.35e-03 | 18 | 103 | 2 | PF00454 | |
| Domain | PI3_4_KINASE_1 | 4.35e-03 | 18 | 103 | 2 | PS00915 | |
| Domain | PI3_4_KINASE_2 | 4.35e-03 | 18 | 103 | 2 | PS00916 | |
| Domain | PI3/4_kinase_cat_dom | 4.35e-03 | 18 | 103 | 2 | IPR000403 | |
| Domain | Cation_ATPase_N | 4.35e-03 | 18 | 103 | 2 | SM00831 | |
| Domain | PI3_4_KINASE_3 | 4.35e-03 | 18 | 103 | 2 | PS50290 | |
| Domain | Cyt_P450 | 4.44e-03 | 60 | 103 | 3 | IPR001128 | |
| Domain | BRCT | 4.84e-03 | 19 | 103 | 2 | PF00533 | |
| Domain | ATPase_P-typ_cation-transptr_N | 4.84e-03 | 19 | 103 | 2 | IPR004014 | |
| Pathway | REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET | 7.02e-06 | 8 | 72 | 3 | M27135 | |
| Pathway | REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE | 1.05e-05 | 9 | 72 | 3 | M27143 | |
| Pathway | REACTOME_CYP2E1_REACTIONS | 2.05e-05 | 11 | 72 | 3 | M27130 | |
| Pathway | WP_OCTADECANOID_FORMATION_FROM_LINOLEIC_ACID | 2.72e-05 | 12 | 72 | 3 | M48064 | |
| Pathway | KEGG_MEDICUS_REFERENCE_DNA_END_RESECTION_AND_RPA_LOADING | 9.87e-05 | 18 | 72 | 3 | M47838 | |
| Pathway | WP_TAMOXIFEN_METABOLISM | 1.59e-04 | 21 | 72 | 3 | M39631 | |
| Pathway | REACTOME_XENOBIOTICS | 2.10e-04 | 23 | 72 | 3 | M5372 | |
| Pathway | WP_ESTROGEN_METABOLISM_WP5276 | 2.39e-04 | 24 | 72 | 3 | M46445 | |
| Pathway | REACTOME_XENOBIOTICS | 2.71e-04 | 25 | 72 | 3 | MM14846 | |
| Pathway | REACTOME_DEUBIQUITINATION | 3.72e-04 | 262 | 72 | 7 | MM15286 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_MARESIN_LIKE_SPMS | 3.81e-04 | 6 | 72 | 2 | M27909 | |
| Pathway | KEGG_LINOLEIC_ACID_METABOLISM | 4.24e-04 | 29 | 72 | 3 | M2920 | |
| Pathway | WP_CANNABINOID_RECEPTOR_SIGNALING | 4.24e-04 | 29 | 72 | 3 | M39676 | |
| Pathway | WP_ARACHIDONATE_EPOXYGENASE_EPOXIDE_HYDROLASE | 5.31e-04 | 7 | 72 | 2 | M39515 | |
| Pathway | REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET | 5.31e-04 | 7 | 72 | 2 | MM14856 | |
| Pathway | REACTOME_BIOSYNTHESIS_OF_MARESINS | 7.06e-04 | 8 | 72 | 2 | M27891 | |
| Pathway | REACTOME_DEUBIQUITINATION | 8.16e-04 | 299 | 72 | 7 | M27574 | |
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 35134542 | ||
| Pubmed | Distribution of CYP2C polymorphisms in an Amerindian population of Brazil. | 2.91e-08 | 3 | 108 | 3 | 21977947 | |
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 23118231 | ||
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 28687336 | ||
| Pubmed | A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. | 2.91e-08 | 3 | 108 | 3 | 8530044 | |
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 21173785 | ||
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 24430292 | ||
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 20665013 | ||
| Pubmed | 2.91e-08 | 3 | 108 | 3 | 27803446 | ||
| Pubmed | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. | 2.91e-08 | 3 | 108 | 3 | 19954515 | |
| Pubmed | Biochemistry and molecular biology of the human CYP2C subfamily. | 1.16e-07 | 4 | 108 | 3 | 7704034 | |
| Pubmed | 1.16e-07 | 4 | 108 | 3 | 28990182 | ||
| Pubmed | 1.16e-07 | 4 | 108 | 3 | 19706858 | ||
| Pubmed | 1.16e-07 | 4 | 108 | 3 | 2009263 | ||
| Pubmed | 1.16e-07 | 4 | 108 | 3 | 21798861 | ||
| Pubmed | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. | 1.16e-07 | 4 | 108 | 3 | 16025294 | |
| Pubmed | 1.16e-07 | 4 | 108 | 3 | 23755828 | ||
| Pubmed | 2.90e-07 | 5 | 108 | 3 | 19415824 | ||
| Pubmed | Prevalence of CYP450 gene variations in patients with type 2 diabetes. | 2.90e-07 | 5 | 108 | 3 | 20857895 | |
| Pubmed | 2.90e-07 | 5 | 108 | 3 | 10698974 | ||
| Pubmed | Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. | 5.78e-07 | 6 | 108 | 3 | 17635176 | |
| Pubmed | 7.44e-07 | 23 | 108 | 4 | 16638864 | ||
| Pubmed | 3.44e-06 | 10 | 108 | 3 | 20602612 | ||
| Pubmed | 3.44e-06 | 10 | 108 | 3 | 19651758 | ||
| Pubmed | Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. | 4.72e-06 | 11 | 108 | 3 | 15469410 | |
| Pubmed | 4.72e-06 | 11 | 108 | 3 | 15039299 | ||
| Pubmed | 8.14e-06 | 13 | 108 | 3 | 22369660 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 7574697 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 30562214 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 26122864 | ||
| Pubmed | Secretory pathway Ca2+ -ATPases promote in vitro microcalcifications in breast cancer cells. | 9.55e-06 | 2 | 108 | 2 | 28618103 | |
| Pubmed | Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. | 9.55e-06 | 2 | 108 | 2 | 12435384 | |
| Pubmed | Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. | 9.55e-06 | 2 | 108 | 2 | 18511451 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 18694831 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 27590274 | ||
| Pubmed | Developmental expression of human hepatic CYP2C9 and CYP2C19. | 9.55e-06 | 2 | 108 | 2 | 14634042 | |
| Pubmed | CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. | 9.55e-06 | 2 | 108 | 2 | 10908295 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 1847130 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19943174 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 28513222 | ||
| Pubmed | Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes. | 9.55e-06 | 2 | 108 | 2 | 17599801 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 15385837 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 25518510 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 16372821 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 15842554 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19136640 | ||
| Pubmed | Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage. | 9.55e-06 | 2 | 108 | 2 | 35748067 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 20890775 | ||
| Pubmed | Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development. | 9.55e-06 | 2 | 108 | 2 | 32587777 | |
| Pubmed | Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. | 9.55e-06 | 2 | 108 | 2 | 17201743 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 32683556 | ||
| Pubmed | Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. | 9.55e-06 | 2 | 108 | 2 | 18548238 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 15855721 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19847408 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 17504998 | ||
| Pubmed | Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. | 9.55e-06 | 2 | 108 | 2 | 24519941 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 14623888 | ||
| Pubmed | Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. | 9.55e-06 | 2 | 108 | 2 | 14646690 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 25939603 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19480553 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 22589111 | ||
| Pubmed | Identification of BRCC3 and BRCA1 as Regulators of TAZ Stability and Activity. | 9.55e-06 | 2 | 108 | 2 | 37887275 | |
| Pubmed | CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. | 9.55e-06 | 2 | 108 | 2 | 15660966 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 18154472 | ||
| Pubmed | Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. | 9.55e-06 | 2 | 108 | 2 | 15766564 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 27353638 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 17298483 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 33115391 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 21047199 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 17562299 | ||
| Pubmed | Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. | 9.55e-06 | 2 | 108 | 2 | 16646575 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 36960518 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 26690534 | ||
| Pubmed | cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. | 9.55e-06 | 2 | 108 | 2 | 3697070 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 16332677 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19199010 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19381162 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19358898 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 34438105 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 2895926 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 19935798 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 20831536 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 16198656 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 24288737 | ||
| Pubmed | [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]. | 9.55e-06 | 2 | 108 | 2 | 15569425 | |
| Pubmed | Death-associated protein kinase 1 variation and Parkinson's disease. | 9.55e-06 | 2 | 108 | 2 | 21749573 | |
| Pubmed | Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. | 9.55e-06 | 2 | 108 | 2 | 22491019 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 28686288 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 20808793 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 15606441 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 32567426 | ||
| Pubmed | Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. | 9.55e-06 | 2 | 108 | 2 | 17868191 | |
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 32868386 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 27617498 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 16873909 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 106274 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 15776277 | ||
| Pubmed | 9.55e-06 | 2 | 108 | 2 | 24492587 | ||
| Pubmed | Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes. | 9.55e-06 | 2 | 108 | 2 | 18940477 | |
| Pubmed | Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. | 9.55e-06 | 2 | 108 | 2 | 16232205 | |
| Interaction | ZNF280D interactions | 6.82e-06 | 24 | 105 | 4 | int:ZNF280D | |
| GeneFamily | Ring finger proteins | 1.01e-04 | 275 | 71 | 7 | 58 | |
| GeneFamily | Ring finger proteins|Fanconi anemia complementation groups|Protein phosphatase 1 regulatory subunits|BRCA1 A complex|BRCA1 B complex|BRCA1 C complex | 1.51e-04 | 5 | 71 | 2 | 1336 | |
| GeneFamily | WD repeat domain containing|Caspase recruitment domain containing|Apoptosome | 2.18e-04 | 30 | 71 | 3 | 959 | |
| GeneFamily | Ring finger proteins|Fanconi anemia complementation groups|Protein phosphatase 1 regulatory subunits|BRCA1 A complex|BRCA1 B complex|BRCA1 C complex | 2.26e-04 | 6 | 71 | 2 | 1328 | |
| GeneFamily | Schlafen family | 3.15e-04 | 7 | 71 | 2 | 1110 | |
| GeneFamily | Cytochrome P450 family 2 | 3.47e-04 | 35 | 71 | 3 | 1001 | |
| GeneFamily | ATPases Ca2+ transporting | 5.38e-04 | 9 | 71 | 2 | 1209 | |
| GeneFamily | WD repeat domain containing|GRAM domain containing|BEACH domain containing | 1.15e-03 | 13 | 71 | 2 | 1146 | |
| GeneFamily | WAP four-disulfide core domain containing|Fibronectin type III domain containing | 2.23e-03 | 18 | 71 | 2 | 361 | |
| Coexpression | HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP | TRIM22 TRIM5 TBC1D8 VPS9D1 ARHGAP5 KARS1 NOD1 TRAFD1 MICB PLSCR2 SLAMF7 | 7.21e-07 | 394 | 108 | 11 | M40996 |
| Coexpression | GSE11961_FOLLICULAR_BCELL_VS_GERMINAL_CENTER_BCELL_DAY7_DN | 1.83e-06 | 200 | 108 | 8 | M9341 | |
| Coexpression | KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP | CCDC117 PDS5B ZNF93 FAM91A1 NBN MCM3 BRCC3 USP37 DICER1 PTP4A1 BRCA1 LRFN5 KLHL23 TPX2 MIB1 DKC1 SLFN11 BRF2 | 5.27e-06 | 1290 | 108 | 18 | M80 |
| Coexpression | JOHNSTONE_PARVB_TARGETS_3_DN | ASNSD1 PDS5B NT5E PHOSPHO2 USP37 MDM4 ATP2C1 MICB MTRFR KLHL23 MIB1 CCAR1 DKC1 SASS6 | 1.50e-05 | 877 | 108 | 14 | M2241 |
| Coexpression | BLANCO_MELO_HUMAN_PARAINFLUENZA_VIRUS_3_INFECTION_A594_CELLS_UP | 2.24e-05 | 204 | 108 | 7 | M34006 | |
| Coexpression | NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE | SMG1 NT5E ZNF195 MDM4 PTP4A1 STAG3L1 CCAR1 STAG3L2 USP48 DYNC1LI2 | 2.71e-05 | 474 | 108 | 10 | M40991 |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C4_CYCLING_NK_CELL | PDS5B SAAL1 MCM3 USP37 BRCA1 SLFN13 MICB MTRFR TPX2 SASS6 CHST2 USP48 | 2.96e-05 | 694 | 108 | 12 | M45767 |
| Coexpression | UROSEVIC_RESPONSE_TO_IMIQUIMOD | 6.28e-05 | 19 | 108 | 3 | M4857 | |
| Coexpression | ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_UP | LRRK2 FAM91A1 NBN CPED1 TRIM22 DICER1 TRIM5 TBC1D8 ACSL3 NOD1 TRAFD1 MICB SLFN11 SLAMF7 | 7.15e-05 | 1012 | 108 | 14 | M40868 |
| Coexpression | SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN | 7.37e-05 | 20 | 108 | 3 | MM1104 | |
| Coexpression | TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_DN | 1.29e-04 | 24 | 108 | 3 | MM708 | |
| Coexpression | GSE9960_HEALTHY_VS_GRAM_POS_SEPSIS_PBMC_DN | 1.69e-04 | 197 | 108 | 6 | M7121 | |
| Coexpression | AFFAR_YY1_TARGETS_DN | 1.75e-04 | 283 | 108 | 7 | MM1157 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C2_CXCL9_POS_MACROPHAGE_CELL | 1.78e-04 | 126 | 108 | 5 | M45721 | |
| Coexpression | GSE42021_TREG_VS_TCONV_PLN_UP | 1.84e-04 | 200 | 108 | 6 | M9572 | |
| Coexpression | GSE45365_NK_CELL_VS_CD8_TCELL_MCMV_INFECTION_DN | 1.84e-04 | 200 | 108 | 6 | M9961 | |
| Coexpression | GSE17812_WT_VS_THPOK_KO_MEMORY_CD8_TCELL_DN | 1.84e-04 | 200 | 108 | 6 | M7164 | |
| Coexpression | GSE17721_0.5H_VS_24H_CPG_BMDC_DN | 1.84e-04 | 200 | 108 | 6 | M4129 | |
| Coexpression | GSE21670_STAT3_KO_VS_WT_CD4_TCELL_TGFB_IL6_TREATED_DN | 1.84e-04 | 200 | 108 | 6 | M7453 | |
| Coexpression | HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_UP | NBN TRIM22 TRIM5 FZD4 NOD1 TRAFD1 SLFN13 MICB NEURL1 TPX2 CLMP PLSCR2 SLAMF7 | 1.86e-04 | 973 | 108 | 13 | M41080 |
| Coexpression | BLANCO_MELO_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_A594_CELLS_UP | 1.87e-04 | 286 | 108 | 7 | M34008 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.67e-06 | 177 | 108 | 6 | 9ec7f1e64312d26d434b3312b58386715dbad644 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.67e-06 | 177 | 108 | 6 | 016277dfd59b1793fddaaadc2b3f41622d76ce3a | |
| ToppCell | Immune_cells-Dendritic_cells|Immune_cells / Lineage and Cell class | 5.48e-06 | 182 | 108 | 6 | 99c7d4f1e7cd745643ba64b59190113bcd4e348e | |
| ToppCell | Control-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | 5.84e-06 | 184 | 108 | 6 | c6affa0b12510363258f65e46bf2d47bf4a8e75f | |
| ToppCell | Control-Epithelial_alveolar-AT_2-Differentiating_AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.02e-06 | 185 | 108 | 6 | 0d2add28ac1f4fa6de7699be009bf8391badaf4c | |
| ToppCell | Control-Myeloid-cDC1|Control / Disease state, Lineage and Cell class | 6.21e-06 | 186 | 108 | 6 | b05c394aa3573ba855abc3066739ca193883b0c3 | |
| ToppCell | 368C-Lymphocytic-NK_cells-NK_cell_D3|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 6.40e-06 | 187 | 108 | 6 | c667fae6440dc98072b584f203d00f0fb1cb2f21 | |
| ToppCell | 3'-GW_trimst-1-SmallIntestine-Hematopoietic-Myeloid-cDC1|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.23e-06 | 191 | 108 | 6 | 9774d423e448ec2d415261e4ad386a81558129b3 | |
| ToppCell | Control-Myeloid-ncMonocyte|Myeloid / Disease state, Lineage and Cell class | 7.67e-06 | 193 | 108 | 6 | 3479c01aaae7afd7e02d00e0cb21951c0106a0fd | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.90e-06 | 194 | 108 | 6 | effd38e51062b225ecabc7e1c50154e65495d559 | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th-Inhibitory_Neuron.Th.Vcan_(SNc)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 1.47e-05 | 61 | 108 | 4 | 12de8c495c7f47ecd720f29a573471705603732a | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th-Inhibitory_Neuron.Th.Vcan_(SNc)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 1.47e-05 | 61 | 108 | 4 | a655232c6d92335eb086723ab9b05eb3a5479b68 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid-cDC1|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.70e-05 | 162 | 108 | 5 | 448602d5ff8b5be9614c63540a4d0fe6bdaf23b4 | |
| ToppCell | Bronchial_Brush-Epithelial-Goblet_2|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X | 5.43e-05 | 167 | 108 | 5 | 806d1c00c137da0c5f042adf866873eb6dd4bb27 | |
| ToppCell | droplet-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l49|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.59e-05 | 168 | 108 | 5 | d2b91f2adc95dcfa623f8d7ca2df1c6f884da988 | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid-Dendritic-dendritic_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.15e-05 | 177 | 108 | 5 | aa56129d2d5a73a10e33b7162233a4d9337ee535 | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid-Dendritic-dendritic_cell-Migratory_DCs-Migratory_DCs_L.1.2.1.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.15e-05 | 177 | 108 | 5 | d78a6003ce2d15d7771ae385de252eec7e3c3eea | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid-Dendritic-dendritic_cell-Migratory_DCs|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.15e-05 | 177 | 108 | 5 | 70ca5b6fde2e38af1eb88a7d6e8746edba298191 | |
| ToppCell | TCGA-Liver-Solid_Tissue_Normal-Liver|TCGA-Liver / Sample_Type by Project: Shred V9 | 7.54e-05 | 179 | 108 | 5 | 0e22e840f43ca81a7543dcf33ec17a741cdf7f37 | |
| ToppCell | TCGA-Liver-Solid_Tissue_Normal-Liver-Liver_normal_tissue|TCGA-Liver / Sample_Type by Project: Shred V9 | 7.54e-05 | 179 | 108 | 5 | 17ba1eedb6ebf039d3b11d099351d0ac6363c8d1 | |
| ToppCell | ASK452-Immune-B_cell|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq | 7.54e-05 | 179 | 108 | 5 | c3cf49c069e66db16d2fce1de4c52a4c4fe7e832 | |
| ToppCell | TCGA-Liver-Solid_Tissue_Normal|TCGA-Liver / Sample_Type by Project: Shred V9 | 7.54e-05 | 179 | 108 | 5 | 7046f0a426e45fe1b41a25721ee1e33f6fc7f9e3 | |
| ToppCell | TCGA-Liver-Solid_Tissue_Normal-Liver-Liver_normal_tissue-2|TCGA-Liver / Sample_Type by Project: Shred V9 | 7.54e-05 | 179 | 108 | 5 | a20bb3ace5be10c5aef330e9268c0ba55f8fee23 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.59e-05 | 184 | 108 | 5 | 42ce855b4f8475a8298192feec785bdc69bc5bb0 | |
| ToppCell | Control-Epithelial_alveolar-AT_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.59e-05 | 184 | 108 | 5 | 51e129b3fcc2df083eda05a3afe3717218b1e52b | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D231|Adult / Lineage, Cell type, age group and donor | 8.81e-05 | 185 | 108 | 5 | fb6bd7e849ecf4ed9cd9c4e2a946a2d12d62f804 | |
| ToppCell | PBMC-Control-cDC_10|Control / Compartment, Disease Groups and Clusters | 8.81e-05 | 185 | 108 | 5 | 4b5a7450fed912f340da16065c1e65d626dbe8d1 | |
| ToppCell | Control-Myeloid-cDC1|World / Disease state, Lineage and Cell class | 9.04e-05 | 186 | 108 | 5 | 3de803dee3ef10eb85a2b47d3f93385214e5b0ff | |
| ToppCell | 368C-Lymphocytic-NK_cells-NK_cell_D3|368C / Donor, Lineage, Cell class and subclass (all cells) | 9.50e-05 | 188 | 108 | 5 | ecc2364d946f97ae0212fd6739960c9fc75e4919 | |
| ToppCell | IPF-Myeloid-cDC1|Myeloid / Disease state, Lineage and Cell class | 9.50e-05 | 188 | 108 | 5 | 47bb6caf84f70a1cda7d09803afdfd5182772e66 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD|kidney_cells / Celltypes from Cells and Nuclei per compartment and clinical group | 9.50e-05 | 188 | 108 | 5 | 90188b60ff893754f7938fe8edab79758827168e | |
| ToppCell | facs-Pancreas-Endocrine-3m-Epithelial-pancreatic_D_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.74e-05 | 189 | 108 | 5 | fcc3713e8200d51074f709f3360fb36efb0a639f | |
| ToppCell | NS-moderate-d_16-33-Epithelial-FOXN4+|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.99e-05 | 190 | 108 | 5 | 250ca4a605c1cccd77d23383e4fe6f91cf3609ba | |
| ToppCell | 3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.02e-04 | 191 | 108 | 5 | f5ce33af56178333730be308253943c54a0724cf | |
| ToppCell | COVID-19-Heart-EC_(POSTN)|Heart / Disease (COVID-19 only), tissue and cell type | 1.05e-04 | 192 | 108 | 5 | c0c34785a7bdf461722029b322e9184e3d9b3c26 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.05e-04 | 192 | 108 | 5 | bc84b9ce01b4d826a682842ab8a395dac9b91183 | |
| ToppCell | TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_NOS-6|TCGA-Stomach / Sample_Type by Project: Shred V9 | 1.05e-04 | 192 | 108 | 5 | 4e689bca7a242f8482e25f273656e2caba8821c0 | |
| ToppCell | 3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.05e-04 | 192 | 108 | 5 | a8b7c539dc3037071bf068f372e4215563e11de4 | |
| ToppCell | 3'-Distal_airway-Mesenchymal-Fibroblastic|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.05e-04 | 192 | 108 | 5 | 2143e1fad2e88b90d668e12af37b2092d379090f | |
| ToppCell | 3'-Distal_airway-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.05e-04 | 192 | 108 | 5 | 904c003c4f73b1dfc8243cee02aad2676c515e50 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.05e-04 | 192 | 108 | 5 | 0ab1176cfbb0de8dd1f22c6e2c41265cf6c10ee1 | |
| ToppCell | 3'_v3-bone_marrow-Myeloid_Monocytic-Nonclassical_monocytes|bone_marrow / Manually curated celltypes from each tissue | 1.07e-04 | 193 | 108 | 5 | dc309c249d569e93dc2b154e002212a6eee44497 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.07e-04 | 193 | 108 | 5 | 9ab47b360bee1d4f1092c2269e58acebe9584021 | |
| ToppCell | myeloid-CD16+_Monocyte|myeloid / Lineage and Cell class | 1.10e-04 | 194 | 108 | 5 | aeeadfeb01827dbc7de6576c76fb2e41a3c59247 | |
| ToppCell | moderate-Epithelial-FOXN4+|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.10e-04 | 194 | 108 | 5 | dff3fb10372053951d41e0ccd41aac3ece6009bd | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Mesenchymal-myocytic-myofibroblast|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.13e-04 | 195 | 108 | 5 | eb2003d4f15cad213d17eda8ab7479f5a0c62164 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Mesenchymal-myocytic|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.13e-04 | 195 | 108 | 5 | 44f67437ea65d530133a0240b17f9860d9cc0e99 | |
| ToppCell | COVID-19_Mild-Non-classical_Monocyte|COVID-19_Mild / Disease condition and Cell class | 1.13e-04 | 195 | 108 | 5 | dd00facd20a661ef23fa7fd9a02ee377b8f2d1b9 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-A|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.13e-04 | 195 | 108 | 5 | 1e28617ca55e5f318a228357737b968dfac8cca0 | |
| ToppCell | COVID-19_Mild-Non-classical_Monocyte-|COVID-19_Mild / Disease condition and Cell class | 1.13e-04 | 195 | 108 | 5 | 0295d9897830987eec74f51178e14fb0a83723dc | |
| ToppCell | 15-Trachea-Mesenchymal-Mesenchyme_SERPINF1-high|Trachea / Age, Tissue, Lineage and Cell class | 1.16e-04 | 196 | 108 | 5 | 54aefcebf13704f51de84379e2e22ec0734b9461 | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_2-Differentiating_AT2|Control_saline / Treatment groups by lineage, cell group, cell type | 1.18e-04 | 197 | 108 | 5 | 44a59dfb889577b3160a5b13ada1276771a00241 | |
| ToppCell | CV-Mild-1|CV / Virus stimulation, Condition and Cluster | 1.21e-04 | 198 | 108 | 5 | 4b078714c49e7befb7b113d72485e712236d35fa | |
| ToppCell | mild-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.24e-04 | 199 | 108 | 5 | f0b0097df0026496470a80d8cc9375ffd8389b00 | |
| ToppCell | ILEUM-inflamed-(8)_Fibroblasts|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.24e-04 | 199 | 108 | 5 | 3a3e2bb21cd0293622b1a975263e918d9ba24265 | |
| ToppCell | Transverse-B_cell-B_cell_cycling|B_cell / Region, Cell class and subclass | 1.24e-04 | 199 | 108 | 5 | 170ae68963d31f3b821b6f0e8f0c039bea0bc981 | |
| Computational | Cytochrome P450. | 5.76e-05 | 14 | 60 | 3 | MODULE_106 | |
| Drug | bufuralol | 1.03e-06 | 5 | 108 | 3 | ctd:C010831 | |
| Drug | 4,4'-cyclohexylidenebisphenol | 2.05e-06 | 6 | 108 | 3 | ctd:C570106 | |
| Drug | 4',5-dihydroxydiclofenac | 2.05e-06 | 6 | 108 | 3 | CID003052567 | |
| Drug | AC1O5Z5L | 2.05e-06 | 6 | 108 | 3 | CID006443527 | |
| Drug | 3'-hydroxydiclofenac | 2.05e-06 | 6 | 108 | 3 | CID000112230 | |
| Drug | nickel nitrate | 2.05e-06 | 6 | 108 | 3 | CID000025736 | |
| Drug | 16-O-demethylaconitine | 3.58e-06 | 7 | 108 | 3 | ctd:C486136 | |
| Drug | 5-fluorotryptamine | 3.58e-06 | 7 | 108 | 3 | ctd:C034536 | |
| Drug | 6-Fluoro-6-desoxyoxymorphone | 3.58e-06 | 7 | 108 | 3 | CID005486899 | |
| Drug | 13-hydroxyeicosatetraenoic acid | 5.71e-06 | 8 | 108 | 3 | CID006439499 | |
| Drug | 11-HODE | 5.71e-06 | 8 | 108 | 3 | CID006438497 | |
| Drug | 5-bromotryptamine | 5.71e-06 | 8 | 108 | 3 | ctd:C040997 | |
| Drug | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | 5.71e-06 | 8 | 108 | 3 | ctd:C585955 | |
| Drug | Tryptamines | 8.54e-06 | 9 | 108 | 3 | ctd:D014363 | |
| Drug | 5-chlorotryptamine | 8.54e-06 | 9 | 108 | 3 | ctd:C529169 | |
| Drug | 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate | 8.54e-06 | 9 | 108 | 3 | ctd:C109602 | |
| Drug | 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid | 8.54e-06 | 9 | 108 | 3 | ctd:C000588958 | |
| Drug | norketobemidone | 1.22e-05 | 10 | 108 | 3 | CID000161154 | |
| Drug | sitaxsentan | 1.22e-05 | 10 | 108 | 3 | ctd:C106276 | |
| Drug | Haloperidol metabolite I | 1.67e-05 | 11 | 108 | 3 | CID000038282 | |
| Drug | trans-1,2-dihydro-1,2-naphthalenediol | 1.67e-05 | 11 | 108 | 3 | ctd:C507866 | |
| Drug | 5-hydroxydiclofenac | 2.21e-05 | 12 | 108 | 3 | CID003052566 | |
| Drug | 4-(N-propionylanilino)piperidine | 2.21e-05 | 12 | 108 | 3 | CID000259381 | |
| Drug | carveol | 2.21e-05 | 12 | 108 | 3 | CID000007438 | |
| Drug | desethylamodiaquine | 2.21e-05 | 12 | 108 | 3 | ctd:C047386 | |
| Drug | norclozapine | 2.21e-05 | 12 | 108 | 3 | ctd:C058272 | |
| Drug | dibenzylfluorescein | 2.23e-05 | 2 | 108 | 2 | ctd:C558664 | |
| Drug | N-bromophthalimide | 2.23e-05 | 2 | 108 | 2 | CID000075542 | |
| Drug | formarin | 2.23e-05 | 2 | 108 | 2 | CID000009333 | |
| Drug | primidone | 2.80e-05 | 37 | 108 | 4 | CID000004909 | |
| Drug | AC1L18GM | 2.87e-05 | 13 | 108 | 3 | CID000000092 | |
| Drug | 7-hydroxyquinoline | 2.87e-05 | 13 | 108 | 3 | CID000011378 | |
| Drug | 1'-hydroxymidazolam | 2.87e-05 | 13 | 108 | 3 | CID000107917 | |
| Drug | clozapine N-oxide | 2.87e-05 | 13 | 108 | 3 | CID000036727 | |
| Drug | propionanilide | 3.64e-05 | 14 | 108 | 3 | CID000012107 | |
| Drug | 5-MeO-DIPT | 3.64e-05 | 14 | 108 | 3 | CID000151182 | |
| Drug | 2'-(glutathion-S-yl)-deschlorodiclofenac | 4.53e-05 | 15 | 108 | 3 | ctd:C586542 | |
| Drug | 4-hydroxymephenytoin | 4.53e-05 | 15 | 108 | 3 | CID000119507 | |
| Drug | L 654969 | 4.66e-05 | 42 | 108 | 4 | CID000005218 | |
| Drug | Ro 31-8959 | 5.01e-05 | 84 | 108 | 5 | CID000060787 | |
| Drug | 4,4'-(hexafluoroisopropylidene)diphenol | 5.56e-05 | 16 | 108 | 3 | ctd:C571725 | |
| Drug | 6-hydroxychlorzoxazone | 5.56e-05 | 16 | 108 | 3 | CID000002734 | |
| Drug | Amodiaquine | 5.56e-05 | 16 | 108 | 3 | ctd:D000655 | |
| Drug | 1-phenylazo-2-naphthol | 5.56e-05 | 16 | 108 | 3 | ctd:C024336 | |
| Drug | picoxystrobin | 6.67e-05 | 3 | 108 | 2 | ctd:C556557 | |
| Drug | Cyclohexenes | 6.67e-05 | 3 | 108 | 2 | ctd:D053138 | |
| Drug | mono-N-demethyladinazolam | 6.67e-05 | 3 | 108 | 2 | ctd:C050132 | |
| Drug | ortho-Aminobenzoates | 6.67e-05 | 3 | 108 | 2 | ctd:D062367 | |
| Drug | 5-(4-(3-(4-cyclohexyl-2-propylphenoxy)propoxy)phenyl)-1,3-oxazolidine-2,4-dione | 6.67e-05 | 3 | 108 | 2 | ctd:C502236 | |
| Drug | 2-hydroxychlorpropamide | 6.67e-05 | 3 | 108 | 2 | CID003082454 | |
| Drug | Delavirdine | 6.67e-05 | 3 | 108 | 2 | ctd:D020008 | |
| Drug | diosmetin | 6.72e-05 | 17 | 108 | 3 | ctd:C039602 | |
| Drug | Azamulinum | 8.04e-05 | 18 | 108 | 3 | CID003086060 | |
| Drug | 7-benzyloxyquinoline | 8.04e-05 | 18 | 108 | 3 | CID003035604 | |
| Drug | pleuromutilin | 8.04e-05 | 18 | 108 | 3 | CID000031326 | |
| Drug | D 703 | 8.04e-05 | 18 | 108 | 3 | CID000054088 | |
| Drug | 2,4-oxazolidinedione | 8.04e-05 | 18 | 108 | 3 | CID000097389 | |
| Drug | hydroxytolbutamide | 9.52e-05 | 19 | 108 | 3 | CID000003656 | |
| Drug | 6|A-Hydroxycortisol | 9.52e-05 | 19 | 108 | 3 | CID000150985 | |
| Drug | lovastatin acid | 1.12e-04 | 20 | 108 | 3 | CID000064727 | |
| Drug | N'-nitrosoanatabine | 1.12e-04 | 20 | 108 | 3 | CID000051291 | |
| Drug | 3C etc | 1.12e-04 | 20 | 108 | 3 | CID000164045 | |
| Drug | tamoxifen N-oxide | 1.12e-04 | 20 | 108 | 3 | CID003033895 | |
| Drug | 3-methoxymorphinan | 1.12e-04 | 20 | 108 | 3 | CID000001671 | |
| Drug | glimepiride | 1.26e-04 | 54 | 108 | 4 | CID000003476 | |
| Drug | AC1LABND | 1.26e-04 | 54 | 108 | 4 | CID000485098 | |
| Drug | AC1L21VM | 1.30e-04 | 21 | 108 | 3 | CID000039524 | |
| Drug | nirvanol | 1.30e-04 | 21 | 108 | 3 | CID000091480 | |
| Drug | zafirlukast | 1.30e-04 | 21 | 108 | 3 | ctd:C062735 | |
| Drug | thiocoraline | 1.33e-04 | 4 | 108 | 2 | ctd:C109005 | |
| Drug | 1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea | 1.33e-04 | 4 | 108 | 2 | ctd:C558737 | |
| Drug | 4-isopropylphenol | 1.33e-04 | 4 | 108 | 2 | ctd:C028690 | |
| Drug | methysticin | 1.33e-04 | 4 | 108 | 2 | ctd:C076881 | |
| Drug | Sulfadiazine | 1.33e-04 | 4 | 108 | 2 | ctd:D013411 | |
| Drug | rabeprazole-thioether | 1.33e-04 | 4 | 108 | 2 | ctd:C523099 | |
| Drug | 7,8-dihydromethysticin | 1.33e-04 | 4 | 108 | 2 | ctd:C107882 | |
| Drug | DBDMH | 1.33e-04 | 4 | 108 | 2 | CID000006479 | |
| Drug | Vincristine | PDS5B CYP2C8 CYP2C9 NT5E MATN2 HECTD4 BIRC3 NBN USP37 CHM TRIM22 ARHGAP5 SLFN13 KLHL23 CCAR1 SLAMF7 | 1.41e-04 | 1182 | 108 | 16 | ctd:D014750 |
| Drug | N'-nitrosoanabasine | 1.50e-04 | 22 | 108 | 3 | CID000014335 | |
| Drug | azoline | 1.50e-04 | 22 | 108 | 3 | CID003013050 | |
| Drug | Bortezomib | CYP2C19 CYP2C9 PSAP NT5E FOLR1 BIRC3 BRCC3 TRAFD1 BRCA1 CCAR1 CHST2 DNM2 BRF2 | 1.70e-04 | 838 | 108 | 13 | ctd:D000069286 |
| Drug | 3'-amino-3'-deoxythymidine | 1.72e-04 | 23 | 108 | 3 | CID000108074 | |
| Drug | N-nitrosomethylethylamine | 1.95e-04 | 24 | 108 | 3 | CID000025418 | |
| Drug | cinnamic acid | 1.95e-04 | 24 | 108 | 3 | ctd:C029010 | |
| Drug | 2-oxo-clopidogrel | 2.21e-04 | 5 | 108 | 2 | ctd:C540904 | |
| Drug | benfuracarb | 2.21e-04 | 5 | 108 | 2 | ctd:C096128 | |
| Drug | mono(2-ethyl-5-hydroxyhexyl) phthalate | 2.21e-04 | 5 | 108 | 2 | ctd:C479069 | |
| Drug | methylpropylnitrosamine | 2.21e-04 | 25 | 108 | 3 | CID000013545 | |
| Drug | Aconitine | 2.21e-04 | 25 | 108 | 3 | ctd:D000157 | |
| Drug | Tranylcypromine | 2.21e-04 | 25 | 108 | 3 | ctd:D014191 | |
| Drug | Tolbutamide | 2.21e-04 | 25 | 108 | 3 | ctd:D014044 | |
| Drug | AC1L44DC | 2.21e-04 | 25 | 108 | 3 | CID000150456 | |
| Drug | Ticlopidine | 2.21e-04 | 25 | 108 | 3 | ctd:D013988 | |
| Drug | N-nitrosopiperidine | 2.21e-04 | 25 | 108 | 3 | CID000007526 | |
| Drug | tegaserod | 2.49e-04 | 26 | 108 | 3 | CID005487301 | |
| Drug | 11-HETE | 2.49e-04 | 26 | 108 | 3 | CID000001406 | |
| Drug | 24-methylenelanost-8-en-3beta-ol | 2.49e-04 | 26 | 108 | 3 | CID000065172 | |
| Drug | adenosine kinase inhibitor | 2.49e-04 | 26 | 108 | 3 | CID000001973 | |
| Drug | 1,4-naphthoquinone | 2.49e-04 | 26 | 108 | 3 | ctd:C035342 | |
| Drug | licochalcone A | 2.79e-04 | 27 | 108 | 3 | ctd:C070840 | |
| Disease | X-21258 measurement | 3.47e-05 | 3 | 101 | 2 | EFO_0800802 | |
| Disease | Hailey-Hailey disease (implicated_via_orthology) | 1.72e-04 | 6 | 101 | 2 | DOID:0050429 (implicated_via_orthology) | |
| Disease | Adenoid Cystic Carcinoma | 3.94e-04 | 100 | 101 | 4 | C0010606 | |
| Disease | testosterone measurement | ATP8B3 CYP2C8 SAAL1 C16orf96 PKDREJ GALNT13 PTP4A1 TBC1D8 GLMN SPOCD1 USP48 USH2A ARHGAP21 | 4.11e-04 | 1275 | 101 | 13 | EFO_0004908 |
| Disease | Malignant neoplasm of salivary gland | 4.98e-04 | 45 | 101 | 3 | C0220636 | |
| Disease | Salivary Gland Neoplasms | 5.66e-04 | 47 | 101 | 3 | C0036095 | |
| Disease | X-11308 measurement | 6.25e-04 | 11 | 101 | 2 | EFO_0800693 | |
| Disease | thymol sulfate measurement | 7.49e-04 | 12 | 101 | 2 | EFO_0021170 | |
| Disease | nervous system disorder | 8.05e-04 | 53 | 101 | 3 | C0027765 | |
| Disease | aplastic anemia (is_implicated_in) | 8.83e-04 | 13 | 101 | 2 | DOID:12449 (is_implicated_in) | |
| Disease | Hereditary Breast and Ovarian Cancer Syndrome | 1.03e-03 | 14 | 101 | 2 | C0677776 | |
| Disease | Rhabdomyosarcoma | 1.18e-03 | 15 | 101 | 2 | C0035412 | |
| Disease | 16a-hydroxy DHEA 3-sulfate measurement | 1.18e-03 | 15 | 101 | 2 | EFO_0800301 | |
| Disease | andro steroid monosulfate C19H28O6S (1) measurement | 1.35e-03 | 16 | 101 | 2 | EFO_0800305 | |
| Disease | MAJOR AFFECTIVE DISORDER 2 | 1.53e-03 | 17 | 101 | 2 | C1839839 | |
| Disease | breast cancer (is_implicated_in) | 1.79e-03 | 150 | 101 | 4 | DOID:1612 (is_implicated_in) | |
| Disease | estrogen-receptor negative breast cancer | 1.88e-03 | 71 | 101 | 3 | EFO_1000650 | |
| Disease | lymphocyte percentage of leukocytes | 2.05e-03 | 665 | 101 | 8 | EFO_0007993 | |
| Disease | urinary bladder cancer (is_implicated_in) | 2.28e-03 | 76 | 101 | 3 | DOID:11054 (is_implicated_in) | |
| Disease | Attention deficit hyperactivity disorder | 3.05e-03 | 24 | 101 | 2 | C1263846 | |
| Disease | osteonecrosis | 3.31e-03 | 25 | 101 | 2 | EFO_0004259 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| IRVLASECIKKLCPV | 336 | Q6ZRH7 | |
| VQVRGLETEKIKCCL | 1196 | P53355 | |
| CPVRKKRITEAELCA | 81 | Q8IWD4 | |
| TVTIGVETPKCLCKV | 606 | A4D0V7 | |
| DPSVLIKTAIRCCKA | 516 | Q8IX12 | |
| CLVEELRKTKASPCD | 151 | P10632 | |
| VVCKDCAPSLRKCPI | 576 | Q13489 | |
| CCRVTPKQKALIVAL | 911 | O60423 | |
| ERVVALICCEKLHKI | 691 | Q9UPY3 | |
| IVKKLPIVETLGCCN | 331 | P98194 | |
| VKKLPIVETLGCCSV | 361 | O75185 | |
| CLVVDKESRKCKAII | 406 | P24386 | |
| AICALCAKDPVKERR | 941 | Q9NTI5 | |
| IEEVKKICSVLGCVE | 431 | O75747 | |
| KISCCPRLKILRLEE | 171 | Q8N9N7 | |
| IGIAVKAQICPKRCV | 11 | Q96NI6 | |
| CSEPCEKGQIKVIRK | 511 | P41594 | |
| CKKCTEGPIDLVFVI | 646 | O00339 | |
| PECKVVKCRFPVVEN | 221 | P15529 | |
| GASCPICKKEIQLVI | 471 | O15151 | |
| DIKICTLPEKCAVDK | 181 | Q658Y4 | |
| PVLVVCTKCDAVSVL | 226 | O43237 | |
| KREDVLKISGPCIVC | 211 | Q9NRY7 | |
| EIVCACPTQPDKVRK | 56 | Q9Y239 | |
| CQVCEKESSPKLVEL | 746 | Q5S007 | |
| KERILNVPLCKEDCE | 126 | P41439 | |
| VIIIILCVPCCKKKT | 321 | Q29980 | |
| KQIIRCPVCLKDLEE | 6 | A6NLU0 | |
| CPVCLKDLEEAVQLK | 11 | A6NLU0 | |
| PRVDKLVEKILHCSC | 106 | P41271 | |
| LKIVVRESCILITKC | 411 | Q9Y4D8 | |
| KEPCLKCVDLVIQEL | 421 | P50570 | |
| KKAPVKSCTECVRVD | 31 | P16144 | |
| RCPKNLCKKVVLIEF | 146 | Q8TCD6 | |
| SLCSPRVKKCLICKE | 841 | Q86YT6 | |
| KEDRKTVVCPIIDVI | 226 | Q8IUC8 | |
| CVEGIVTKCSLVRPK | 126 | P25205 | |
| RKVLDCEKPGISCLT | 886 | Q13797 | |
| ICLELIKEPVSTKCD | 26 | P38398 | |
| CLSVKRRCEPVLKEF | 121 | Q9ULV1 | |
| IPCLQKRCIDKFKAT | 1846 | Q86XA9 | |
| CPELEKESRRILCSK | 151 | Q8NBE8 | |
| VCLNKEVTCKREKCP | 71 | Q8N8U9 | |
| EVTCKREKCPVLSRD | 76 | Q8N8U9 | |
| CLVEELRKTKASPCD | 151 | P33261 | |
| LFKRVKCISCDRPVE | 906 | A6NNT2 | |
| PCLTKVELRVACKGI | 21 | Q96A23 | |
| LQKKEVLVGCCVLIT | 111 | Q9HAW0 | |
| VLKDCCKILDNTVLP | 121 | Q9BTE1 | |
| VEVKKVMACPRCILT | 261 | Q969Z3 | |
| SVAVKKRVLCLPRDE | 291 | Q9NWL6 | |
| LKDCIVHLCISKPER | 31 | P31321 | |
| EKCVKNLCRTPQLII | 196 | Q6UWM5 | |
| ECRKETLIITPPSCK | 6846 | Q8NDH2 | |
| CLVEELRKTKASPCD | 151 | P11712 | |
| VPLEEVVLKVCSCAL | 81 | Q8IUY3 | |
| PKVTGCLIVCIERAT | 126 | O60832 | |
| PLQVKCKDCEERRVS | 11 | Q6UVJ0 | |
| VLAKSKCPRLREICV | 101 | Q96ER3 | |
| GKVCVRAKVLCLSPE | 506 | Q68D06 | |
| RVCRLKEKELEALPC | 1101 | Q9BXL7 | |
| KERVLNVPLCKEDCE | 126 | P15328 | |
| ICIKACREPKISDLV | 341 | Q6UXH9 | |
| DGKLLEVIERKRCVC | 776 | Q6ZVC0 | |
| VGPVVRCLLCKDKED | 66 | Q92990 | |
| ELCKAVRCQKPESIC | 3166 | O75445 | |
| KQIIRCPVCLKDLEE | 6 | F8VTS6 | |
| CPVCLKDLEEAVQLK | 11 | F8VTS6 | |
| CKCDILKVLGIQVVV | 296 | Q8WVZ7 | |
| KKHEETECPLRLAVC | 76 | O14545 | |
| KILDDICVAKAVECP | 421 | Q15046 | |
| KVTIKTICALICGRP | 156 | O60934 | |
| PACTVKKARVVCLPV | 1046 | Q9NTG1 | |
| PVCEDQLKEIERCIK | 2736 | Q96Q15 | |
| GKVCVRAKVLCLSPE | 506 | Q7Z7L1 | |
| KKPVIIAATKCDECV | 191 | Q13017 | |
| KVTCRDVLPEIRAIC | 11 | P0CL83 | |
| LCSEAVPLLVKVIKC | 951 | O60518 | |
| GDRVVKLDVLCTKCR | 466 | P21589 | |
| KVCLESAVELPKILC | 226 | P46736 | |
| RVGAPLVCCEIKLKN | 496 | O95573 | |
| TEIKRVAEEKVTLPC | 21 | Q9H6B4 | |
| VVGLVDDRVCKKCPP | 271 | Q9Y4C5 | |
| VCCPKELLEQKAVLE | 186 | Q969H4 | |
| LVNVKEEVTCPICLE | 6 | Q9C035 | |
| DEVKCRVLLCDPEAK | 501 | Q14690 | |
| LKRCITDETCPGVKK | 86 | Q8IUB2 | |
| LQLIKRCESVDECKV | 111 | P35789 | |
| CVVLKHIPSGIVVKC | 81 | Q9H3J6 | |
| CCPICRRPIKDIIKT | 556 | O76050 | |
| KASVCKTIACLLPED | 391 | Q13129 | |
| CVRCVPTDKAIKKFV | 26 | Q5JNZ5 | |
| LASICPAKAKDVCVV | 916 | Q6ZMY3 | |
| DIKIEVFCERTPKTC | 11 | Q9H2H8 | |
| CCKIILPLREVVSIE | 336 | O95759 | |
| EVKISICKTISCLLP | 366 | O60281 | |
| KVTCRDVLPEIRAIC | 11 | P0CL84 | |
| EKKRVDICRETPNIC | 261 | Q9NQ25 | |
| PTVKSLPCDICKDVV | 56 | P07602 | |
| SIICKACGEIIPKRE | 486 | Q86T82 | |
| KVTCRDVLPEIRAIC | 11 | P0CL85 | |
| LESCPQKKLECIVRT | 521 | Q9Y2B5 | |
| TVRPCFLPCKKDCIV | 726 | Q9C0I4 | |
| IPLIVDICCKLVEER | 1161 | Q5T5U3 | |
| PRLTVKALCKECVVE | 546 | Q86UV5 | |
| KVDIEKEVTCPICLE | 6 | Q8IYM9 | |
| KTHPICLCLDKVEVE | 76 | Q6BDS2 | |
| SLVKIKFREEPGCCI | 86 | Q93096 | |
| RIKVCEKRPSIDLCI | 31 | Q8IUB3 | |
| TVCKPGLITCLEQRK | 46 | O14628 | |
| KAKRCATPVIIDEIL | 141 | Q9ULW0 | |
| RKIEAKTEEVICPLT | 321 | Q8N1T3 |